Showing results (211-220 of 427) with videos related to

Sort By:
Pageof 43
Leukemia Research|August 17, 2010
"Real-life" results of front-line treatment with Imatinib in older patients (≥ 65 years) with newly diagnosed chronic myelogenous leukemiaRoberto Latagliata, Massimo Breccia, Ida Carmosino, et al.
Annals of Hematology|October 14, 2024
Different prognosis according to treatment in patients with acute promyelocytic leukemia: How the outcome changed over timeEmilia Scalzulli, Alessandro Costa, Ida Carmosino, et al.
Blood|April 5, 2003
Chronic lymphocytic leukemia patients with highly stable and indolent disease show distinctive phenotypic and genotypic featuresAnna Guarini, Gianluca Gaidano, Francesca Romana Mauro, et al.
Leukemia & Lymphoma|April 7, 2010
Darbepoetin alfa for the treatment of anemia associated with myelodysplastic syndromes: efficacy and quality of lifeEsther N Oliva, Francesco Nobile, Giuliana Alimena, et al.
Leukemia Research|June 2, 2009
Second-generation tyrosine kinase inhibitors before allogeneic stem cell transplantation in patients with chronic myeloid leukemia resistant to imatinibMassimo Breccia, Francesca Palandri, Anna Paola Iori, et al.
Annals of Hematology|May 1, 2012
Which health-related quality of life aspects are important to patients with chronic myeloid leukemia receiving targeted therapies and to health care professionals? GIMEMA and EORTC Quality of Life GroupFabio Efficace, Massimo Breccia, Susanne Saussele, et al.
Blood|June 10, 2004
Gemtuzumab ozogamicin (Mylotarg) as a single agent for molecularly relapsed acute promyelocytic leukemiaFrancesco Lo-Coco, Giuseppe Cimino, Massimo Breccia, et al.
Annals of Hematology|June 29, 2018
Prolonged treatment with arsenic trioxide (ATO) and all-trans-retinoic acid (ATRA) for relapsed acute promyelocytic leukemia previously treated with ATRA and chemotherapyLaura Cicconi, Massimo Breccia, Luca Franceschini, et al.
Cancer|April 21, 2012
Evaluation of residual CD34(+) Ph(+) progenitor cells in chronic myeloid leukemia patients who have complete cytogenetic response during first-line nilotinib therapyMarzia Defina, Micaela Ippoliti, Alessandro Gozzetti, et al.
Annals of Hematology|January 8, 2021
Mortality rate in patients with chronic myeloid leukemia in chronic phase treated with frontline second generation tyrosine kinase inhibitors: a retrospective analysis by the monitoring registries of the Italian Medicines Agency (AIFA)Massimo Breccia, Simone Celant, Pier Paolo Olimpieri, et al.
Pageof 43